3 not yet recruiting, 1 recruiting, 1 unknown. 5 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Not yet recruiting 3, Recruiting 1, Unknown 1 |
| Phase 1 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow EGFR Mutation: new trials by email Literature Review of EGFR Mutation trials Research Report on EGFR Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer ANS014004 + PLB1004, ANS014004 + Osimertinib - Non-Small Cell Lung Cancer, EGFR Mutation | Phase 1 / Phase 2 | Not yet recruiting | Beijing Pearl Biotechnology Limited Liability Company | 253 | 2026-06-01 | 2025-12-16 |
| Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study Furmonertinib, carboplatin, pemetrexed - Non-small Cell Lung Cancer (NSCLC), Brain Metastases | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 60 | 2026-01-01 | 2026-01-26 |
| High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastasis Combination therapy prospective cohort - Non Small Cell Lung Cancer, EGFR Mutation | Phase 2 | Not yet recruiting | Qiming Wang | 100 | 2025-05-15 | 2025-05-14 |
| First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) BAY2927088_formulation A, BAY2927088_formulation B_1, BAY2927088_formulation B_2 - Advanced Non-small Cell Lung Cancer, EGFR Mutation | Phase 1 / Phase 2 | Recruiting | Bayer | 430 | 2021-10-25 | 2026-10-21 |
| Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation gefitinib, Berberine - Lung Adenocarcinoma, EGFR Mutation | Phase 2 | Unknown | Fujian Cancer Hospital | 50 | 2018-06-05 | 2018-04-03 |
Carcinoma, Non-Small-Cell Lung (3) · Adenocarcinoma of Lung (1) · Brain Neoplasms (1) · Lung Neoplasms (1) · Meningeal Carcinomatosis (1)
Neoplasms (4) · Neoplasms by Site (4) · Respiratory Tract Neoplasms (4) · Thoracic Neoplasms (4) · Bronchial Neoplasms (3) · Carcinoma, Bronchogenic (3) · Lung Diseases (3) · Lung Neoplasms (3) · Respiratory Tract Diseases (3) · Central Nervous System Neoplasms (2) · Nervous System Diseases (2) · Nervous System Neoplasms (2) · Adenocarcinoma (1) · Brain Diseases (1) · Carcinoma (1)
Berberine (1) · Carboplatin (1) · Gefitinib (1) · Pemetrexed (1) · aflutinib (1) · osimertinib (1)
Bayer (1) · Beijing Pearl Biotechnology Limited Liability Company (1) · Fujian Cancer Hospital (1) · Qiming Wang (1) · Tianjin Medical University Cancer Institute and Hospital (1)
China (3) · United States (2) · Belgium (1) · Brazil (1) · France (1) · Hong Kong (1) · Israel (1) · Italy (1) · Japan (1) · Netherlands (1) · Poland (1) · Portugal (1) · Singapore (1) · South Korea (1) · Spain (1)
Cheng Huang, MD. (1)
2023 (1)